[Angioplasty stenting with Sirolimus (rapamycin) eluting stents in type 2 diabetic patients].
BACKGROUND
Drug-eluting stents have been developed to reduce the rates of restenosis after coronary angioplasty. Several studies have demonstrated that rapamycin eluting stents are reliable and effective.


OBJECTIVE
To report the experience in our Health Centre with rapamycin-eluting stents.


METHODS
Forty two stents with rapamicine were implanted to 32 diabetic patients, between June 2002 and December 2004. After the procedure, subjects were clinically followed-up for an average period of 19.9+/-9.9 months, evaluating functional capacity, angina pectoris, dyspnea, need for hospital admission, acute coronary events and cardiac death. In those subjects clinically suspected to have restenosis, a coronary angiography was performed.


RESULTS
Twenty-nine subjects (90.6%) remained asymptomatic, two subjects (6.3%) developed angina pectoris but restenosis was ruled out, and one subject (3.1%) died.


CONCLUSIONS
The use of rapamycin-eluting stents in these patients was safe and successful with no evidence of clinic restenosis. These positive results are similar to those reported in the Diabetes Study.
Ruiz
Carolina B
CB
Servicio de Medicina Interna, Hospital DIPRECA, Santiago, Chile.
Delgado
Mario D
MD
Martínez
Carolina C
CC
Valdivieso
Alicia V
AV
Aylwin
Carmen Gloria H
CG
Deck
Carlos R
CR
Alcaíno
Milton I
MI
D017130:Angioplasty; D016009:Chi-Square Distribution; D023903:Coronary Restenosis / Q000517:prevention & control; D023921:Coronary Stenosis / Q000628:therapy*; D003924:Diabetes Mellitus, Type 2 / Q000628:therapy; D003925:Diabetic Angiopathies / Q000628:therapy*; D054855:Drug-Eluting Stents; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D015203:Reproducibility of Results; D020123:Sirolimus / Q000627:therapeutic use*; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D020123:Sirolimus